

PhenoBench: Mapping What a Deeply Phenotyped Human Cohort Can Tell Us

Gal Sapir^{1,2}, Alon Diamant¹, Adva Wolf¹, Doron Yaya-Stupp², Dikla Gelbard Solodkin¹, Dana Azouri¹, Anat Etzion-Fuchs¹, Guy Lutsker^{2,3}, Eran Segal^{2,4}, Hagai Rossman^{1,4,*}

¹Pheno.AI, Tel Aviv, Israel; ²Department of Computer Science and Applied Mathematics, Weizmann Institute of Science, Rehovot, Israel; ³Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel; ⁴Mohamed bin Zayed University of Artificial Intelligence, Abu Dhabi, UAE

Abstract

Deeply phenotyped cohorts measure clinical, imaging, molecular, and wearable modalities in the same participants, combining dense observations across timescales from seconds to days with longitudinal follow-up over years. This breadth can reveal which measurements inform which health-related questions, but results from heterogeneous analyses are not directly comparable. We present PhenoBench, an executable benchmark built around the Human Phenotype Project, in which more than 13,000 participants have completed the initial visit. Each PhenoBench question fixes the target, eligible population, timing, and allowed information; its evaluation contract specifies the split, metric, baseline, and claim boundary. The current benchmark defines 90 clinically grounded tasks across 15 domains and 26 input modalities. Measurements showed question- and representation-dependent predictive value, including positive, near-zero, and negative changes in held-out performance relative to matched baselines. As one controlled demonstration, we used PhenoBench to evaluate emerging tabular foundation models across 160 matched regression comparisons spanning 52 tasks. These models ranked above standard task-specific models in aggregate but, averaged across the three pretrained models within each cell, improved on ridge by a median of only 0.004 R^2 (95% CI, 0.002–0.006). We then used the same cohort data and evaluation contracts to evaluate 14 language models, collectively covering 40 PhenoBench tasks spanning phenotype recovery, classification, follow-up forecasting, and participant ordering. Without cohort-specific fitting, language models made informative predictions on some tasks, but showed task-specific capability gaps, shared failures of scale, and rarely surpassed models fitted on the same fields. PhenoBench turns a multimodal longitudinal cohort into a versioned, auditable evaluation system where new questions, measurements, and models can be added without redefining existing comparisons.

1. Introduction

Biomedical benchmarks typically compare models on predefined tasks within a particular data type or clinical setting. Deeply phenotyped cohorts create a different opportunity: their breadth can reveal which measurements inform which questions about human health, under what conditions, and by how much. Realizing that promise requires turning this breadth into comparable evidence across well-defined clinical and scientific questions. PhenoBench addresses this challenge using the Human Phenotype Project (HPP), translating its measurements into clinically grounded questions with explicit, comparable evaluation contracts.

The HPP is a large prospective longitudinal cohort, with more than 13,000 participants having completed the initial visit [19]. Its design combines dense monitoring over days with clinical, imaging, and molecular profiling and repeated follow-up over years. This supports two complementary views: which measurements inform a given question, and which questions each measurement can help answer. The HPP dataset records what was measured, while individual studies estimate how informative particular measurements are for particular questions. Because those studies use different populations, inputs, splits, baselines, and methods, their findings cannot be directly compared. A common evaluation basis allows their evidence to accumulate.

Shared benchmarks offer one way to create this common evaluation basis by expressing biomedical data as fixed tasks, splits, and metrics. PhysioNet Challenges established this model around clinically motivated problems [22], and EHRSHOT extended it to longitudinal structured EHR data by defining 15 prediction

tasks for evaluating reusable representations [23]. Extending this principle to deep-phenotyping data poses a different task-definition problem. Physiological time series, imaging, clinical assays, and omics collected outside routine care are not accompanied by the structured diagnoses, interventions, or care pathways available in routine-care data. Clinically meaningful targets, eligible populations, temporal relations, and baselines must therefore be constructed explicitly. Defining a shared set of evaluation tasks from these data is thus a distinct benchmarking problem.

Pretrained models increasingly support strong tabular and time-series prediction with little or no task-specific training [5–7], while general-purpose language models are used for health questions at extraordinary scale: more than 300 million people ask ChatGPT health-related questions each week [25]. Evaluating these models requires specifying which question to ask, who is eligible, what information is available and when, which baseline is relevant, and how success is measured [3]. In health, these choices encode clinical judgment and determine which comparisons are meaningful and what claims the results can support.

Here, we use the Human Phenotype Project (HPP) [19] to build PhenoBench: a set of clinically grounded questions expressed as explicit evaluation contracts, and a common framework for comparing measurements and methods across them. PhenoBench supports two complementary views: which measurements help answer a given question, and which questions each measurement can help answer. Across these evaluations, we examine how predictive value varies across measurements, questions, and methods, and where predictive headroom remains. We first use PhenoBench to compare emerging tabular models against conventional machine-learning baselines across compatible tasks. We then use the same physician-reviewed questions and evaluation contracts to test language-model predictions from cohort data. Together, this turns the breadth of HPP into comparable evidence about what a deeply phenotyped cohort can tell us.

2. Results

2.1. Mapping clinically grounded questions across HPP

We organized HPP measurements into 90 evaluation tasks spanning cross-modal phenotype prediction, longitudinal prediction, sequence and event prediction, retrieval and matching, and causal effect estimation. These tasks cover 15 clinical domains and 26 input modalities (Figure 1A-B), with measurement windows and task horizons spanning seconds to years (Figure 1D). Participant-level evaluation cohorts range from 537 to 11,726 people.

The initial questions were drawn from prior HPP studies and a clinician-authored inventory of clinically interpretable target measurements, then expanded as PhenoBench developed. Each question was documented in a human-readable Task Card recording the target, relevant measurements, cohort, timing, clinical context, metric, and baseline, then implemented as an executable PhenoBench task (Methods and Appendix A).

Each task expresses a scientific or clinical question. A valid comparison then fixes the population, split, allowed information, metric, and relevant baseline. Figure 1C shows how a question becomes a fixed comparison; Figure 2 applies these comparisons in two directions: asking which measurements inform a given question and which questions a given measurement can help answer. Within either view, holding the method fixed isolates differences among information sources, while holding the information source fixed isolates differences among methods.

2.2. Mapping predictive information across tasks

Figure 2 presents PhenoBench evidence in two directions. The measurement-first view asks which questions can be predicted from a given measurement; continuous glucose monitoring (CGM) and overnight sleep monitoring (WatchPAT) are shown across several clinical domains and output types (Figure 2A). Because the examples use different cohorts and outcomes, their effect sizes should not be compared across questions. The full registered task set is shown in Supplementary Figure 1.

In the question-first view, the question, cohort, split, metric, baseline, and ridge model are held fixed while the measurement changes (Figure 2B). Which measurement appeared most informative depended on the question: CGM had the largest validation-set ΔR^2 point estimate for fasting glucose, whereas WatchPAT had the largest for chronological age, and neither was strongest for both. Small and negative validation-set ΔR^2 values are




Figure 1 | The HPP question space and how PhenoBench turns measurements into comparable evidence across timescales. **A**, PhenoBench organizes 90 clinically grounded tasks across 15 clinical domains. Each domain is illustrated by a representative question; symbols indicate the task type. **B**, Questions span phenotype prediction, longitudinal prediction, sequence and event prediction, retrieval and matching, and causal effect estimation. **C**, Worked example for HbA1c prediction. A scientific question is translated into an executable task that fixes the target, cohort, timing, data splits, and evaluation metric. Predefined information sets, such as demographics, continuous glucose monitoring, or retinal imaging, are evaluated using compatible methods under fixed conditions. These comparisons estimate how much predictive information is available through each prespecified measurement–representation route and how effectively different methods use the same route. **D**, Illustrative measurement windows and task horizons span seconds to years on a continuous, approximately logarithmic axis; the 1–6-year region is expanded for legibility. Task examples include baseline-to-follow-up horizons at 2, 4, and 6 years. Examples are selected rather than exhaustive, and positions communicate timescale rather than exact duration.

retained; negative values indicate that adding the representation reduced performance relative to the matched baseline. Together, the two views show selective, question-dependent predictive value rather than a universal best measurement.




Figure 2 | Two complementary readings of PhenoBench evidence. **A**, CGM and WatchPAT are each linked through available derived or learned representations to example questions spanning metabolic, cardiovascular, microbiome, retinal, aging, and sequence outcomes. Figure 2A entries report the representation, evidence split, metric, and total cohort size. The post-meal entry reports absolute RMSE because it has no matched comparator; the other scalar entries report ΔR^2 , the held-out R^2 of a ridge probe with the listed representation minus that of the matched ridge probe without it. These entries use separate cohorts, so their effect sizes should not be compared. The GluFormer example is descriptive: its upstream CGM encoder was trained across all canonical splits, so it is not interpreted as held-out evidence. **B**, Fasting glucose and chronological age are each evaluated with CGM, electrocardiography (ECG), WatchPAT, and dual-energy X-ray absorptiometry (DXA). CGM, ECG, and WatchPAT use frozen Chronos-2 embeddings; DXA uses six curated features. Within each question, participants, split, ridge strategy, demographic comparator, and ΔR^2 metric are fixed. Circles show point estimates and lines show 95% bootstrap intervals. These matched validation refits quantify predictive association for specified measurement–representation routes, not causality or clinical utility.

2.3. Comparing model families on matched tasks

Across 160 matched test-set comparison cells spanning 52 tasks, the pretrained tabular models TabSwift [20], TabICL [6], and TabDPT [27] were compared with three task-specific baselines—ridge regression, gradient-boosted trees, and RealMLP [26]—while holding the task, cohort, feature set, and split fixed (Figure 3). The pretrained models ranked higher overall but, averaged across the three pretrained models within each cell, their improvement over ridge had a median of only 0.004 R^2 (95% CI, 0.002–0.006). In 121 of 160 cells, the mean ΔR^2 across the three pretrained models exceeded the mean across ridge and RealMLP (signed-rank $p = 6 \times 10^{-15}$; sign-test $p = 6 \times 10^{-11}$); 10 of 15 pairwise contrasts among all six methods remained significant after correction for multiple comparisons. Ridge exceeded gradient-boosted trees in 96 of 160 cells, a difference that did not survive correction. Across these HPP tasks, the pretrained models’ better aggregate rank did not translate into large held-out gains over ridge.

Features extracted by frozen, zero-shot Chronos-2 [7], a pretrained time-series model, underperformed engineered features from the same signal in 25 of 31 CGM comparisons ($p = 0.002$) and 30 of 32 WatchPAT comparisons ($p = 9 \times 10^{-9}$). Where Chronos-2 glucose embeddings performed better, gains were concentrated in three metabolic targets: for fasting plasma glucose, ΔR^2 was 0.201 with embeddings versus 0.169 with engineered features; for GlycA, an NMR marker of systemic inflammation, 0.099 versus 0.067; and for the triglyceride–glucose index, 0.082 versus 0.061. The gap narrowed with larger training cohorts, suggesting

limited sample efficiency when fitting a ridge model to the high-dimensional embeddings.




Figure 3 | Model families on matched clinical comparisons. **A**, Mean rank of each method within a comparison cell (1 = best) across 160 cells in which all six methods ran on the same task, cohort, feature set, and split, spanning 52 tasks; bars are bootstrap 95% intervals. **B**, ΔR^2 over demographics by feature set; boxes show quartiles, whiskers 1.5 IQR, outliers omitted; cell counts differ and the fundus and glucose groups are thin. **C**, Fraction of cells in which the row model exceeded the column model among the pretrained tabular models; the asterisk marks the one pair significant after Holm correction under both a signed-rank and a sign test. **D**, Frozen zero-shot Chronos-2 embeddings are compared with engineered features from the *same* signal using the same ridge head. CGM pairs share tasks and cohorts; WatchPAT pairs are matched on task only and use different cohorts. The labeled fatty-liver-index failure combines a 3,076-dimensional embedding with 710 training participants; the demographics-only baseline reached $R^2 = 0.79$. ΔR^2 is measured against the same demographics-only ridge baseline within each cell.

2.4. PhenoBench-LLM: cohort data as a controlled test of LLM capability

We evaluated 14 language models using a frozen prompt and per-participant evidence packet containing age, sex, BMI, 19 CGM summary metrics, and 33 Nightingale NMR measurements. Individual models covered 22–

40 of 40 PhenoBench tasks spanning phenotype recovery, classification, follow-up forecasting, and participant ordering, with 150–480 validation participants per task (Figure 4 and Methods). PhenoBench reserves this split for development.

The tasks revealed distinct capability profiles (Figure 4A): Gemini 3.7 Flash led overall (common-task win rate, 82.5%; 95% CI, 67.1–94.4) and in three categories, Claude Opus 4.8 led classification, and GPT-5.4 nano performed better in follow-up forecasting than in phenotype recovery or classification. The eleven tasks shared by all models comprised six ordering, three classification, and two phenotype-recovery tasks. On this set, cost did not determine performance: Llama 4 Maverick, GPT-5.6, and Gemini 3.7 Flash formed the Pareto frontier (Figure 4B).

Task-specific fitted models generally outperformed the language models across phenotype recovery, classification, and ordering. Across phenotype-recovery tasks, language models exceeded a ridge probe fitted on the same fields in only 9 of 304 model–task cells. Most language models exceeded the demographic baseline in follow-up forecasting, but same-field ridge models performed better. The tasks also exposed failures hidden by aggregate rankings. Every model predicted retinal artery width on a micrometre-like rather than the target’s AutoMorph-pixel scale; retinal artery width remained off-scale under both card versions. Taken together, these HPP evaluations show that newer model families did not consistently improve on matched task-specific baselines. Appendix D reports detailed estimates, probe comparisons, reliability analyses, and failure modes. These validation results are descriptive and specific to the tested tasks, packets, and prompt.




Figure 4 | Cohort data maps LLM capability and efficiency. **A**, Each cell is a model’s within-category pairwise win rate against other LLMs, computed only from available head-to-heads on the same task; values are percentages and higher is better. Rows are ordered by overall win rate on the 11 tasks shared by all 14 models. Grey cells indicate that a model was not evaluated in that category. Category coverage differs, and native metrics are never compared across categories. **B**, Pairwise win rate against other LLMs on the 11 shared tasks versus mean cost per call. Vertical lines are 95% bootstrap confidence intervals across tasks; numbers identify model rows in A. A model remains on the Pareto frontier when every cheaper model has a lower win rate.

3. Methods

3.1. Study design

The Human Phenotype Project (HPP) is a prospective longitudinal cohort with broad clinical, molecular, imaging, and wearable phenotyping [19]. PhenoBench analyses use task-specific eligible subsets rather than one common cohort. Participants are assigned to canonical 70/15/15 train, validation, and test splits, with repeated observations grouped by participant; fitted preprocessing uses training data only, model development uses validation data, and reviewed final results use the held-out test split. HPP participants provided informed consent, and identifying details were removed before computational analysis. The study was conducted according to the Declaration of Helsinki and approved by the Weizmann Institute of Science Institutional Review Board (approval 2392-4) [19].

3.2. Evaluations

A model-comparison cell fixes the task, cohort, predictor, evaluation split, target, participants, and feature set while varying the fitting method. The regression capacity analysis compared ridge, gradient boosting, RealMLP, TabSwift, TabICL, and TabDPT in 160 complete test-set cells spanning 52 tasks. The time-series analysis compared frozen, zero-shot Chronos-2 embeddings with features engineered from the same signal under a linear ridge head. PhenoBench-LLM used fixed evidence packets and Task contracts to compare language-model predictions with demographic and fitted-probe references. Schema-faithful synthetic bundles expose the complete external-model input and output contract without releasing participant data. Full cohort construction, model configurations, preprocessing, provenance, exclusions, and evaluation contracts are reported in the Extended Methods.

3.3. Analysis

For model-capacity comparisons, ΔR^2 was the full-model test R^2 minus the common demographics-only ridge baseline from the matched ridge run, and the comparison cell was the inferential unit. The reported 0.004 R^2 advantage is the median across the 160 cells of the within-cell mean ΔR^2 of the three pretrained models minus ridge ΔR^2 . Mean ranks used bootstrap 95% intervals; the Friedman test assessed omnibus differences, an ordering-free within-cell mean contrast compared pretrained and conventional models, Page’s test assessed the ordered capacity sequence, and paired Wilcoxon signed-rank and exact binomial sign tests were corrected separately with the Holm procedure. Same-signal Chronos-2 comparisons used paired tests at their available matching unit. Detailed estimands, matching rules, resampling, permutation analyses, and statistical assumptions are reported in the Extended Methods.

4. Discussion

“To measure is to know” is often attributed to Lord Kelvin. What he wrote was more precise: “when you can measure what you are speaking about, and express it in numbers, you know something about it” [16]. He did not have deeply phenotyped cohorts in mind. Yet these cohorts become more useful when their breadth can be expressed as answers to specific questions: which measurements inform which outcomes, under what conditions, and by how much. PhenoBench provides a common basis for making those answers comparable. The same basis lets us ask how predictive information varies across measurements and how different model families use it.

HPP is particularly suited to this approach because it measures the same participants across clinical, imaging, molecular, and wearable modalities, over timescales ranging from seconds to years. By holding the clinical question and evaluation conditions fixed, PhenoBench can compare how different measurements and models use this breadth. New tabular models can therefore be evaluated across every compatible task, while language-model-based predictors can be assessed on physician-reviewed questions under the same contracts.

Across 90 clinically grounded tasks, which measurements appeared informative depended on the question and representation. This breadth allowed emerging model families to be tested across many matched clinical problems rather than on isolated benchmarks. Pretrained tabular models ranked higher overall but improved only slightly over ridge; a recent clinical comparison likewise found limited gains over optimized baselines

[17]. Engineered glucose and sleep features often outperformed Chronos-2 embeddings of the same signals. These comparisons show where a model family helps, where gains disappear against a matched baseline, and where additional data may change the answer.

Medical model benchmarks often begin with questions already distilled into vignettes, fixed prediction tasks, or simulated clinical workflows [22–24]. PhenoBench makes the upstream clinical and scientific work visible: defining the target, eligible population, timing, available information, comparator, and metric is central to determining what a result means. Human-readable Task Cards record the clinical rationale, and executable evaluation contracts enforce the resulting conditions. Once these are fixed, a new model can be evaluated without redefining the question, making performance differences easier to interpret.

PhenoBench is designed to grow as a versioned evidence record. New tasks, measurements, models, and results can be added while each released version remains fixed. Because every result retains its question, evaluation conditions, and provenance, later studies can determine whether a changed answer reflects stronger evidence, a different method, or a different question.

AI capability remains a “jagged frontier” [4]: performance on one task does not predict performance on an adjacent one. PhenoBench-LLM showed this directly across 14 models and four task categories. Models had distinct profiles across phenotype recovery, classification, follow-up forecasting, and ordering; cost did not determine performance; and task-specific fitted models generally performed better. Fixed participants, evidence, targets, and metrics made these differences interpretable and exposed shared failures of scale and target semantics. PhenoBench-LLM therefore provides a repeatable way to test how language models use cohort evidence as models, prompts, and evidence encoders change.

LLM agents can increasingly propose, execute, and revise analyses [18]. Reliable use requires a verification loop that checks each output against a defined question, held-out data, metric, comparator, and supporting evidence. The separate machine-querying experiment in Appendix C provides an initial test of whether models can navigate this evidence faithfully. With explicit rewards and protected final tasks, PhenoBench could also serve as a post-training environment for agentic research workflows [1,2].

PhenoBench turns a deeply phenotyped cohort into a shared system for asking which measurements inform which health questions and which models can use that information. Fixing the task, cohort, available data, comparator, and metric allows new tasks and models to extend a cumulative record without redefining earlier comparisons.

4.1. Limitations

Benchmark rankings may reify biases in HPP recruitment and measurement coverage, predictive associations may be mistaken for causal or clinically actionable evidence, and detailed health data could compromise privacy if released without controls. We mitigate these risks by retaining null results and claim boundaries, requiring matched comparisons and provenance, reporting subgroup and cohort limitations, and keeping individual-level HPP data de-identified and access controlled.

Coverage remains uneven because measurements and methods have not been evaluated on every compatible question, and cross-task summaries combine related tasks with different cohorts and outcomes. Results reflect HPP recruitment and measurement practices, so generalizability to other cohorts remains untested. Same-signal comparators are incomplete, and PhenoBench-LLM uses validation data under one prompt and evidence contract. Appendix F provides further details.

5. Public benchmark leaderboards

The [public PhenoBench release](#) provides the complete task catalog, Task Cards, synthetic input/output examples, per-Track results, and a manual container-submission path; source and contribution instructions are available in the [public repository](#). The compact tables below summarize the two model comparisons reported in the paper. PhenoBench does not define a universal score across heterogeneous tasks or metrics.

Compact model-family leaderboard. Mean within-cell rank across the 160 matched cells shown in Figure 3; lower is better. Rankings compare methods only inside cells with the same task, cohort, feature set, and split.

Model	Mean rank
TabDPT	2.34
TabICL	2.88
TabSwift	3.17
RealMLP	3.66
Ridge	4.11
GBDT	4.84

Common-task PhenoBench-LLM leaderboard. Pairwise win rate on the eleven Tasks evaluated by all 14 models; intervals use a Task-level bootstrap. Native metrics are compared only within a Task, and this validation-set summary is descriptive.

Model	Win rate	95% CI
Gemini 3.7 Flash	82.5%	67.1–94.4%
Claude Opus 4.8	73.4%	63.6–82.5%
Claude Sonnet 5	72.7%	61.5–83.9%
Gemini 3.1 Pro	63.3%	44.4–81.1%
GPT-5.6	62.2%	46.9–76.9%
Gemini 3.1 Flash-Lite	56.6%	46.2–68.5%
Claude Haiku 4.5	47.2%	31.8–63.6%
Nova Pro	46.9%	36.4–57.3%
Grok 4.3	46.2%	32.2–60.1%
Llama 4 Maverick	39.5%	25.2–54.9%
Llama 3.3 70B	32.9%	15.4–52.4%
DeepSeek V4 Pro	30.1%	15.4–46.2%
Pixtral Large	25.9%	5.6–48.3%
GPT-5.4 nano	20.6%	8.0–35.7%

6. Competing interests

Gal Sapir, Alon Diamant, Adva Wolf, Dikla Gelbard Solodkin, Dana Azouri, Anat Etzion-Fuchs, and Hagai Rossman are employees of Pheno.AI Ltd. Eran Segal is a paid consultant of Pheno.AI Ltd.

7. References

1. OpenAI. Learning to reason with LLMs. 2024. <https://openai.com/index/learning-to-reason-with-llms/>
2. Guo D, Yang D, Zhang H, et al. DeepSeek-R1 incentivizes reasoning in LLMs through reinforcement learning. *Nature*. 2025;645:633–638. <https://doi.org/10.1038/s41586-025-09422-z>
3. Raji ID, Bender EM, Paullada A, Denton E, Hanna A. AI and the Everything in the Whole Wide World Benchmark. 2021. <https://doi.org/10.48550/arXiv.2111.15366>
4. Dell’Acqua F, McFowland E III, Mollick E, et al. Navigating the Jagged Technological Frontier: Field Experimental Evidence of the Effects of Artificial Intelligence on Knowledge Worker Productivity and Quality. *Organization Science*. 2026;37:403–423. <https://doi.org/10.1287/orsc.2025.21838>
5. Hollmann N, Müller S, Purucker L, et al. Accurate predictions on small data with a tabular foundation model. *Nature*. 2025;637:319–326. <https://doi.org/10.1038/s41586-024-08328-6>
6. Qu J, Holzmüller D, Varoquaux G, Le Morvan M. TabICL: A Tabular Foundation Model for In-Context Learning on Large Data. 2025. <https://doi.org/10.48550/arXiv.2502.05564>
7. Ansari AF, Shchur O, Küken J, et al. Chronos-2: From Univariate to Universal Forecasting. 2025. <https://doi.org/10.48550/arXiv.2510.15821>
8. Thompson WH, Wright J, Bissett PG, Poldrack RA. Dataset decay and the problem of sequential analyses on open datasets. *eLife*. 2020;9:e53498. <https://doi.org/10.7554/eLife.53498>
9. Huffman JE. Examining the current standards for genetic discovery and replication in the era of mega-biobanks. *Nature Communications*. 2018;9:5054. <https://doi.org/10.1038/s41467-018-07348-x>
10. Dwork C, Feldman V, Hardt M, et al. The reusable holdout: Preserving validity in adaptive data analysis. *Science*. 2015;349:636–638. <https://doi.org/10.1126/science.aaa9375>

11. Gibson MJ, Spiga F, Campbell A, et al. Reporting and methodological quality of studies that use Mendelian randomisation in UK Biobank: a meta-epidemiological study. *BMJ Evidence-Based Medicine*. 2023;28:103–110. <https://doi.org/10.1136/bmjebm-2022-112006>
12. Shilo S, Talmor-Barkan Y, Gorodetski M, et al. Heterogeneity of insulin resistance surrogates in thousands of non-diabetic adults: multi-modal data reveals discordant metabolic phenotypes. *medRxiv*. 2026. <https://doi.org/10.64898/2026.05.02.26352290>
13. Diamant A, Gorodetski M, Jankelow A, et al. A multimodal dataset of 21,412 recorded nights for sleep and respiratory research. *arXiv*. 2023. <https://doi.org/10.48550/arXiv.2311.08979>
14. Shkolnik M, Sapir G, Shilo S, et al. Day-to-day dietary variation shapes overnight sleep physiology: a target-trial emulation in 4.8 thousand person-nights. *medRxiv*. 2026. <https://doi.org/10.64898/2026.02.17.26346471>
15. Reicher L, Bar N, Godneva A, et al. Phenome-wide associations of human aging uncover sex-specific dynamics. *Nature Aging*. 2024;4:1643–1655. <https://doi.org/10.1038/s43587-024-00734-9>
16. Thomson W. Electrical Units of Measurement. In: *Popular Lectures and Addresses*. Vol. 1, Constitution of Matter. London: Macmillan and Co.; 1889:73–136. Lecture delivered May 3, 1883. <https://archive.org/details/popularlecturesa01kelvuoft/page/72/mode/2up>
17. Shaktah LA, Gustav M, Lenz T, et al. Established Machine Learning Matches Tabular Foundation Models in Clinical Predictions. *medRxiv*. 2026. <https://doi.org/10.64898/2026.02.02.26345274>
18. Liu J, Pei J, Huang J, et al. The Last Human-Written Paper: Agent-Native Research Artifacts. *arXiv*. 2026. <https://doi.org/10.48550/arXiv.2604.24658>
19. Reicher L, Shilo S, Godneva A, et al. Deep phenotyping of health–disease continuum in the Human Phenotype Project. *Nature Medicine*. 2025;31:3191–3203. <https://doi.org/10.1038/s41591-025-03790-9>
20. Liu S-Y, Ye H-J. TabSwift: An Efficient Tabular Foundation Model with Row-Wise Attention. *arXiv*. 2026. <https://doi.org/10.48550/arXiv.2606.07345>
21. UK AI Security Institute. Inspect AI: Framework for Large Language Model Evaluations. 2024. https://github.com/UKGovernmentBEIS/inspect_ai
22. PhysioNet. George B. Moody PhysioNet Challenges. <https://physionet.org/about/challenge/>. Accessed September 4, 2026.
23. Wornow M, Thapa R, Steinberg E, Fries JA, Shah NH. EHRSHOT: An EHR Benchmark for Few-Shot Evaluation of Foundation Models. *arXiv*. 2023. <https://doi.org/10.48550/arXiv.2307.02028>
24. Jiang Y, Black KC, Geng G, et al. MedAgentBench: A Virtual EHR Environment to Benchmark Medical LLM Agents. *NEJM AI*. 2025;2(9):Aidbp2500144. <https://doi.org/10.1056/Aidbp2500144>
25. OpenAI. Launching Health in ChatGPT. 2026. <https://openai.com/index/health-in-chatgpt/>
26. Holzmüller D, Grinsztajn L, Steinwart I. Better by Default: Strong Pre-Tuned MLPs and Boosted Trees on Tabular Data. *arXiv*. 2024. <https://doi.org/10.48550/arXiv.2407.04491>
27. Ma J, Thomas V, Hosseinzadeh R, et al. TabDPT: Scaling Tabular Foundation Models on Real Data. *arXiv*. 2024. <https://doi.org/10.48550/arXiv.2410.18164>
28. Page EB. Ordered Hypotheses for Multiple Treatments: A Significance Test for Linear Ranks. *Journal of the American Statistical Association*. 1963;58:216–230. <https://doi.org/10.1080/01621459.1963.10500843>
29. OpenRouter. OpenRouter documentation. <https://openrouter.ai/docs>. Accessed August 26, 2026.
30. Bergenstal RM, Beck RW, Close KL, et al. Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring. *Diabetes Care*. 2018;41:2275–2280. <https://doi.org/10.2337/dc18-1581>
31. Bedi S, Cui H, Fuentes M, et al. MedHELM: Holistic Evaluation of Large Language Models for Medical Tasks. *arXiv*. 2025. <https://doi.org/10.48550/arXiv.2505.23802>

A. Task curation and ingestion audit

The publication-led ingestion workflow converged on a staged, human-first review rather than a direct paper-to-code translation.

Stage	Question answered	Review product
Frame the search	Which questions can the HPP answer, and with which data?	Candidate question and relevant measurement types
Review HPP publications	Which clinical questions were answered or attempted in studies using the cohort?	Source-linked candidate tasks
Extract the task structure	What are the target, cohort, timepoint, information source, metric, comparison, and reported result?	Structured candidate record and short task name
Assemble clinical context	Why does the question matter, how is the target measured, and what are the caveats and meaningful comparators?	Human-readable Task Card grounded in literature and clinical review
Translate into PhenoBench	Does the candidate require a new Task or a new Predictor, Strategy, configuration, metric, or artifact?	Executable contract with explicit provenance
Review real evidence	Does the implementation run on the intended cohort, and how closely does it match the source study?	Run record, baseline comparison, comparability label, and bounded claim

A clinician-authored surrogate-target inventory also seeded clinically interpretable questions, and later benchmark work added question families not represented in the reviewed publications. These inputs broadened the collection, but the table above describes the paper-ingestion process used to turn prior HPP work into reviewable tasks.

The June 2026 corpus pass considered 61 materialized study directories. It generated 31 candidate asset families and assigned every study to one implementation queue:

Queue	Studies	Interpretation
Executable with existing PhenoBench components	13	Existing Task, Predictor, Strategy, metric, and configuration patterns were sufficient to test a paper-inspired row
Required a reviewed artifact	11	The benchmark could consume the result, but a versioned feature, embedding, or prediction artifact was missing
Required a reusable benchmark capability	15	A target shape, split policy, scorer, data route, or provenance rule was missing
Required manual design	6	The direction was plausible, but target choice or claim semantics required an author decision
Rejected or deferred	16	No selected benchmark question, duplicated coverage, protocol or reference context only, or inadequate paper evidence

The 13 executable studies were then checked against real PhenoBench runs and the original result anchors. One produced a close paper-inspired comparison, ten produced useful but non-parity analogues, and two produced weak rows. This second pass changed the ingestion criterion: a runnable configuration was no longer considered sufficient. Each applied row also required a real-data result, a relevant baseline, an explicit comparability label, and a statement of what could not be claimed.

Representative mappings illustrate why a study did not imply one new Task. The insulin-resistance study by Shilo et al. supplied VAT questions that primarily reused an existing target while expanding information-source and configuration coverage [12]. The sleep-resource study by Diamant et al. supported a resting-heart-rate target and a sleep-derived Predictor, with its published comparison retained as an interpretation anchor [13]. The day-to-day diet and sleep study required an event-level, temporally ordered contract and artifact

provenance rather than a conventional participant-level scalar row [14]. The phenome-wide aging study by Reicher et al. reused chronological age as an evaluation target while treating system-specific age models and their outputs as versioned artifacts [15].

A.1. Task Card evolution and contribution path

Task Cards were introduced after the earliest executable Tasks, then backfilled as the task inventory expanded. The converged authoring process in the Methods is therefore the prospective contribution contract, not a claim that every historical Task was originally created card-first.

A Task Card provides a compact, human-readable specification before implementation details dominate the discussion:

Task Card field	Content
Question and target	The clinical or scientific question, endpoint definition, unit, and timing
HPP measurement binding	Source fields or derivation, cohort, quality control, exclusions, and evaluation grain
Clinical context	Why the target matters and what the literature supports
Evaluation plan	Metrics, demographic floor, stronger comparators, and data-split constraints
Risks and limits	Leakage, confounding, noise, nonclaims, and unresolved domain questions
Provenance	Source publications, supporting searches, review status, and linked executable task

A new contribution follows the same review path:


1. State the scientific question and whether it is an exact reproduction, an adaptation, or a paper-inspired analogue.
2. Bind the target to a documented HPP field or derivation, including units, timing, quality control, exclusions, and evaluation grain.
3. Decide whether the proposal requires a new Task or only a new information source, representation, method, or configuration for an existing Task.
4. Create or revise the Task Card before implementation-dependent scientific choices harden.
5. Define the baseline and comparison set before examining held-out results.
6. Implement the smallest executable contract and test it on synthetic data.
7. Run the real-data comparison, inspect support and provenance, and record a paper-faithful, analogue, weak, or non-comparable interpretation.
8. Reconcile the Task Card against the implementation and original evidence, leaving unresolved questions explicit for domain review.

Task code owns enforceable target and scoring facts. Configurations and Predictors own the available information and timepoints. Strategies and run artifacts own the fitted model and predictions. Task Cards own scientific meaning, comparator rationale, caveats, and claim boundaries. This separation allows task definitions to accumulate without embedding paper-specific extraction logic or model-specific assumptions in the target itself.

A.2. Extended results: Mapping information value across tasks

The registered collection comprises 90 clinical Tasks across 15 domains and includes continuous regression, categorical classification, sequence, causal-effect, and ranking targets (Supplementary Figure 1). Three framework-only diagnostics are excluded from these counts. The main-text examples are continuous-valued and illustrate rather than exhaustively sample this breadth.

For scalar tasks, ΔR^2 compares a ridge probe using demographics plus the listed representation with a same-run demographic-only ridge probe on the same participants and folds; demographics comprise age,



Supplementary Figure 1 | Registered clinical Tasks by domain and prediction target type. PhenoBench contains 90 registered clinical Tasks across 15 clinical domains. Stacked segments denote continuous regression, categorical classification, or other sequence, causal-effect, and ranking targets. Three framework-only diagnostics are excluded. Bar length counts registered Tasks and does not represent evaluated performance.

sex, and BMI, except that age is omitted when chronological age is the target. In the measurement-first examples, CGM representations gave ΔR^2 estimates of 0.195 (95% bootstrap interval, 0.090–0.285; validation) for fasting glucose, 0.091 (0.062–0.120; test) for LDL cholesterol, and 0.018 (0.001–0.037; test) for gut microbial diversity. Derived CGM features predicted two-hour post-meal trajectories with a test RMSE of 16.1 mg/dL across 39,412 meals. This is absolute forecast performance rather than an incremental information estimate because that card has no matched comparator. For sleep physiology, Chronos-2 embeddings gave estimates of 0.526 (0.472–0.575; validation) for chronological age and 0.303 (0.236–0.360; validation) for QT interval; derived features gave estimates of 0.016 (–0.012–0.047; test) for the triglyceride–glucose (TyG) index and 0.011 (0.000–0.022; test) for retinal artery width. These examples differ in cohort, outcome, and representation and therefore describe observed routes rather than rank tasks or measurements.

Among 18 CGM-summary evaluations covering 16 distinct tasks, examples included fasting glucose (ΔR^2 , 0.169; 95% bootstrap interval, 0.084–0.247), LDL cholesterol (0.057; 0.034–0.081), total branched-chain amino acids (0.034; 0.014–0.055), and retinal artery tortuosity (–0.009; –0.018 to –0.001). Among 27 WatchPAT-summary evaluations covering 15 distinct tasks, examples included QT interval (0.271; 0.229–0.309), QTc interval (0.034; 0.015–0.054), retinal artery width (0.011; 0.000–0.022), and retinal artery fractal dimension at the later visit (–0.014; –0.025 to –0.004). These are evaluation rows rather than independent tasks because some targets appear in more than one benchmark track. The intervals quantify within-row uncertainty, are not adjusted for multiplicity, and are not used to classify rows as discoveries or null results.

Within matched question-first comparisons, fasting-glucose point estimates ranged from –0.048 for ECG and –0.029 for WatchPAT to 0.035 for DXA and 0.145 for CGM. For chronological age, the corresponding estimates were 0.505 for WatchPAT (95% bootstrap interval, 0.443–0.567), 0.092 for ECG (0.044–0.139), 0.090 for DXA (0.040–0.138), and 0.032 for CGM (–0.037–0.096). These marginal intervals describe each route; they are not paired intervals for differences between routes. Comparisons are made within question only because the two questions use different cohorts.

For fasting glucose, the reported CGM estimates differ by representation, split, and cohort: 0.195 uses Chronos-2 on validation participants ($n = 2,380$), 0.145 uses Chronos-2 on the matched four-measurement validation cohort ($n = 1,816$), and the test-cohort estimates ($n = 6,843$) are 0.169 for engineered summaries and 0.201 for Chronos-2.

B. Model-capacity supporting analyses

B.1. Analysis population and model roles

Figure 3 used 160 complete test-set cells spanning 52 tasks, each with the same target, cohort, feature set, split, and all six methods. In total, 20 cells across 10 tasks were excluded because at least one method was absent: apnea–hypopnea index, estimated glomerular filtration rate, gut Shannon diversity, gut species richness, minimum nocturnal oxygen saturation, next-night sleep, oxygen desaturation index, sleep efficiency, total sleep time, and urate. Eleven cells lacked RealMLP, TabDPT, TabICL, and TabSwift; nine lacked RealMLP, TabDPT, and TabICL. These are availability exclusions, not performance exclusions.

Method	Role in Figure 3	Frozen implementation
Ridge	Linear classical probe and common demographic baseline	PhenoBench persisted run configuration
Gradient boosting	Nonlinear tree baseline	PhenoBench persisted run configuration
RealMLP	Strong neural tabular baseline trained from scratch [26]	pytabkit 1.7.3
TabSwift	Pretrained tabular model [20]	Pinned source revision and checkpoint, with full identities persisted alongside each run; 31.3 MB of checkpoint tensors, approximately 8 million parameters
TabICL	Pretrained tabular model [6]	tabicl 2.1.1; checkpoint identity persisted with each run; 108.9 MB of checkpoint tensors, approximately 29 million parameters
TabDPT	Pretrained tabular model [27]	tabdpt 1.2.0; checkpoint identity persisted with each run; 63,507,568 parameters across 647 float32 tensors (32 layers, embedding width 512, 8 heads)

The 52 engineered-feature partners used only for Panel D were retained as exploratory figure evidence rather than leaderboard rows. Panel A orders methods by nominal capacity: model class for the classical probes, and pretrained parameter count for the three pretrained models. TabDPT’s count is read exactly from its checkpoint metadata; the other two are inferred from checkpoint tensor volume, and their ordering is unchanged whether those checkpoints are read as float32 or float16.

The gradient-boosting tuning grid was amended after exploratory fits on these same comparison cells, while the other five methods retained their original grids; comparisons involving gradient boosting are therefore descriptive.

B.2. Ordered and pairwise method comparisons

As a sensitivity analysis, Page’s ordered-alternative test over ridge, RealMLP, TabSwift, TabICL, and TabDPT gave Page’s $L = 7,797$ across 160 blocks ($p = 1.87 \times 10^{-21}$). The sequence used model class for ridge and RealMLP and pretrained parameter count for the three foundation models; because this rationale was documented after results existed, we treat the analysis as descriptive rather than confirmatory. The least-favorable within-foundation-model ordering also yielded an increasing trend ($L = 7,559$; $p = 6.88 \times 10^{-9}$). Gradient boosting was not included in either ordered sequence. The full pairwise family is below. “Robust” required both Holm-adjusted tests to be below 0.05; values below 10^{-4} are shown as $< 10^{-4}$.

Contrast	First method wins	Signed-rank p_{Holm}	Sign-test p_{Holm}	Robust
Ridge vs gradient boosting	96/160	0.0583	0.0700	No
Ridge vs RealMLP	70/160	0.0096	0.2656	No
Ridge vs TabSwift	52/160	$< 10^{-4}$	0.0001	Yes
Ridge vs TabICL	47/160	$< 10^{-4}$	$< 10^{-4}$	Yes
Ridge vs TabDPT	37/160	$< 10^{-4}$	$< 10^{-4}$	Yes
Gradient boosting vs RealMLP	38/160	$< 10^{-4}$	$< 10^{-4}$	Yes
Gradient boosting vs TabSwift	33/160	$< 10^{-4}$	$< 10^{-4}$	Yes
Gradient boosting vs TabICL	32/160	$< 10^{-4}$	$< 10^{-4}$	Yes
Gradient boosting vs TabDPT	19/160	$< 10^{-4}$	$< 10^{-4}$	Yes
RealMLP vs TabSwift	67/160	0.0583	0.1433	No
RealMLP vs TabICL	56/160	0.0004	0.0011	Yes
RealMLP vs TabDPT	39/160	$< 10^{-4}$	$< 10^{-4}$	Yes
TabSwift vs TabICL	72/160	0.0583	0.2656	No
TabSwift vs TabDPT	53/160	$< 10^{-4}$	0.0002	Yes
TabICL vs TabDPT	66/160	0.0583	0.1299	No

Task identity explained more variation in method advantage than feature-set identity ($\eta^2 = 0.54$ versus 0.07). In 5,000 permutations, the task association exceeded its permuted null; the feature-set association did not when feature-set labels were permuted within task ($p = 0.2424$). These analyses use cells as the sampling unit and should not be interpreted as 160 independent clinical questions.

B.3. Same-signal time-series comparison

Panel D compares a frozen zero-shot Chronos-2 representation with engineered features from the same input signal, both read by ridge. It does not compare raw signals and does not evaluate a tabular foundation model on the embeddings.

Signal	Matching unit	Pairs	Chronos-2 better	Signed-rank p	Sign-test p
CGM	Task and cohort	31	6	0.00159	0.000878
Sleep	Task only; no shared cohorts	32	2	8.85×10^{-9}	2.46×10^{-7}
ECG	No engineered ECG predictor exists	0	–	–	–

The results were insensitive to the most negative pair: after dropping the fatty-liver-index comparison, the signed-rank p values were 0.00299 for glucose and 1.77×10^{-8} for sleep. The engineered-feature advantage narrowed with training size (Spearman correlation between the Chronos-2-minus-engineered gap and training size: 0.594 for glucose and 0.503 for sleep). In the larger half of each modality, the signed-rank result was not significant for glucose (16 pairs; $p = 0.597$) but remained significant for sleep (16 pairs; $p = 0.000305$). Thus Panel D combines representation differences with the sample efficiency of fitting a ridge head to 770–3,076-dimensional embeddings.

The binary-outcome extension was omitted from the main figure because it contained only 12 complete cells spanning 6 tasks. The Friedman test was significant ($p = 3.0 \times 10^{-5}$): gradient boosting ranked last, while no pairwise contrast among the other five methods was significant before correction. The Figure 3 synthesis was post hoc rather than preregistered. Bootstrap intervals describe variation across cells; paired between-method confidence intervals within individual cells were unavailable.

C. Machine-querying PhenoBench evidence

This appendix reports an additional evaluation of whether tool-using language models can query a frozen PhenoBench evidence snapshot. Extended Data Figure 1 summarizes the experiment.

C.1. Results

We tested whether tool-using language models could retrieve and compare PhenoBench evidence while preserving the conditions that make each comparison valid. The questions tested five operations: retrieving a displayed result; selecting a method while holding the task and information source fixed; selecting an information source while holding the task and method fixed; combining a Task Card constraint with leaderboard evidence; and deciding whether two rows were comparable under the benchmark contract (Extended Data Figure 1 and Evaluation design below). Answers had to include the supporting rows, allowing conclusion and evidence fidelity to be assessed separately. Outputs were graded deterministically against 277 reviewed reference answers and independently recomputed from raw model transcripts.

High exact fidelity was feasible but not general across the tested models. Claude Sonnet 4.5 achieved mean accuracies of 94.9% for descriptive lookup, 93.1% for method selection with complete candidate evidence, 88.9% across the nine eligible information-source cases, and 91.7% for context-integrated selection. Other models were uneven: for example, Claude Opus 4.8 achieved 96.4% lookup accuracy but 51.1% method-selection accuracy, whereas Claude Haiku 4.5 achieved 58.7% and 83.9%, respectively. These differences show that reading a result, selecting within a controlled comparison and preserving its evidence are distinct capabilities.

Task Card access increased context-question accuracy for six of seven models by 22.9–68.8 percentage points relative to the leaderboard-only control. This effect is deliberately narrow: the questions required one reviewed card fact that was absent from the leaderboard. Pixtral was the exception, falling from 27.1% without cards to 0% with cards. Transcript inspection showed a model–tool interoperability failure: after reading the card, 46 of 48 runs serialized the next leaderboard request as answer text rather than issuing a tool call. Explicit comparison rules showed a related distinction between conclusions and evidence. Six models returned the correct supported/unsupported verdict on every rule item, but their exact verdict-plus-reason-plus-evidence fidelity ranged from 25.0% to 100%; Pixtral achieved 77.1% verdict fidelity and 24.0% full fidelity.

These results establish that querying benchmark evidence is itself measurable: some tested models achieved high exact fidelity, whereas others failed selectively at comparison, evidence preservation or tool use. They do not establish open-ended scientific reasoning, clinical decision quality or general model superiority.

C.2. Evaluation design

We tested whether tool-using language models could answer natural-language questions from a frozen, version-pinned PhenoBench evidence snapshot. The tools returned leaderboard rows, Task Cards, or the two rows in a specified comparison case; the models had no other route to benchmark data. A manually reviewed bank contained 277 questions: 46 descriptive leaderboard lookups, 174 method comparisons that fixed the task,

information source and evaluation identity, 9 information-source comparisons that fixed the task, method and evaluation identity, 16 questions that required combining a Task Card fact with leaderboard evidence, and 32 minimal pairs testing an explicit four-field comparability rule. The nine information-source questions exhaust the eligible controlled comparisons in the frozen snapshot and are therefore interpreted cautiously.

We implemented the evaluation in Inspect AI v0.3.258 [21], which recorded the prompts, tool calls, model outputs and scoring results for every sample. We evaluated seven Bedrock-hosted model versions: Claude Sonnet 4.5, Claude Haiku 4.5, Claude Opus 4.8, Nova Pro, Nova 2 Lite, Llama 3.3 70B and Pixtral Large 25.02. Each model answered every question in three epochs. Temperature was zero where the provider exposed that setting; the Opus endpoint did not. Prompts, tool definitions, maximum output length, message limit and deterministic grader were otherwise fixed. Sustained quota failures prevented completion through the prespecified US Pixtral inference profile, so before starting a complete Pixtral run we prospectively amended only its AWS routing profile from US to EU; the underlying `pixtral-large-2502-v1:0` model version and all experimental inputs were unchanged, and incomplete US logs were excluded.


Primary correctness was construct-specific. Descriptive lookup required the exact row, metric name and displayed value. Method and information-source comparisons additionally required the complete candidate-row evidence from the controlled set. Context questions required the correct Task Card fact and, when the requirement was satisfied, the exact leaderboard selection; when it was not satisfied, the model had to return no selection. Comparability questions were scored primarily on the supported/unsupported verdict, with exact reason codes and row evidence reported separately. The context questions were repeated in a leaderboard-only control with the Task Card tool removed. All 277 reference answers were audited before the confirmatory run. A second verifier parsed raw model completions independently of the runtime grader, recomputed every primary outcome, checked exact question coverage and frozen-file hashes, and priced recorded token use.

We report each model and construct separately as the arithmetic mean and range of its three epoch accuracies. Repeated epochs over the same question bank were not pooled as independent observations, and no item-level confidence interval was computed from them. No cross-construct endpoint was prespecified or used for inference. For visual compression only, Extended Data Figure 1C adds a post hoc arithmetic mean that assigns each of the five displayed operations equal weight; it is labeled descriptive, and every component remains visible.


C.3. Limitations

The machine-querying experiment measures exact adherence to a frozen benchmark interface, not open-ended scientific reasoning. Reference answers were reviewed against one PhenoBench snapshot and explicit comparison rules, and results may depend on the prompts, tool schema, evaluation harness and provider implementation. Coverage was uneven: information-source selection comprised only nine eligible cases, and the Task Card analysis used eight reviewed facts encoded as matched satisfied and unsatisfied questions. Because these questions were designed to require information absent from the leaderboard, the ablation tests whether models can use necessary Task Card context, not whether Task Cards generally improve research quality. Repeated epochs reused the same items and are not independent samples. Model-tool failures, including Pixtral’s serialized tool calls, therefore characterize the tested model-harness combination rather than the model alone. High interface accuracy does not establish biomedical reasoning quality, clinical utility, PhenoBench-LLM performance, autonomous research or general model superiority.


A Natural-language access




B Example queries



C Performance by operation



D Context and rule fidelity



Extended Data Figure 1 | Tool-using language models query PhenoBench evidence with model-dependent reliability. **A**, A tool-using language model receives a natural-language research question, inspects frozen leaderboard rows, Task Cards and comparison rules, and returns a grounded answer with row evidence. Outputs were checked against 277 reviewed reference answers by deterministic grading and independent replay. **B**, Shortened examples show controlled information-source selection, Task Card-dependent selection or abstention, and a valid/invalid comparison-rule pair. **C**, Grouped bars show each model's mean exact accuracy across three epochs for descriptive lookup ($n = 46$), controlled method selection ($n = 174$), controlled information-source selection ($n = 9$), Task Card-integrated selection ($n = 16$) and comparison-rule verdicts ($n = 32$); whiskers show the epoch range. Open circles and printed values give the equal-weight arithmetic mean of the five operation means. This mean was added post hoc for visual compression, is descriptive only and is not a prespecified endpoint or general model ranking. **D**, Task Card access is compared with leaderboard-only access for the context-dependent questions, and exact comparison verdicts are compared with full verdict-plus-reason-plus-evidence fidelity. Task Cards improved context accuracy for six models but exposed a Pixtral tool-loop failure; comparison verdicts were generally more reliable than full outputs. Reference answers and source facts were reviewed before the run, and a second implementation parsed raw completions and independently recomputed all outcomes. Results are limited to the tested models, prompts, tools and frozen snapshot.

D. PhenoBench-LLM supplementary evidence

D.1. Extended results: PhenoBench-LLM

We next used cohort data to evaluate language models under controlled, clinically grounded conditions. Fourteen frontier language models from eight developers, spanning flagship, mid-size and small tiers, were asked the same HPP questions from the same per-participant evidence packet (demographics, CGM summaries, Nightingale NMR metabolomics, and optionally the Task Card) under a frozen prompt, and their answers entered PhenoBench as Imported Prediction Artifacts scored by 40 existing Tasks in four categories: recovering a hidden measured phenotype (25 Tasks, R^2), classifying a curated status (5 Tasks, AUROC), forecasting a measurement at the two-year follow-up visit from the baseline packet (4 Tasks, R^2), and ordering groups of four participants (6 Tasks, pairwise accuracy), on 150–480 validation participants per Task (Figure 4, Supplementary Figure 2 and Methods). Every cell is one Eval Run whose row-level output was verified against the artifact, and every number was reproduced by an independent implementation.

Cohort Tasks revealed distinct capability profiles (Figure 4A). By pairwise win rate over all available head-to-heads, Gemini 3.7 Flash won 79% (95% CI 71–86), Claude Sonnet 5 70% (61–77) and Claude Opus 4.8 68% (59–77), while Llama 3.3 70B and Pixtral Large won 32% and GPT-5.4 nano 30% (21–39). The ordering was similar on the eleven Tasks run by every model (Gemini 3.7 Flash 83%, Opus 4.8 73%, Sonnet 5 73%; GPT-5.4 nano 21%), but category profiles were not interchangeable. Opus 4.8 led classification head-to-heads (82%), Gemini 3.7 Flash led phenotype recovery (76%), follow-up forecasting (86%) and ordering (91%), and GPT-5.4 nano rose from 23–33% in phenotype recovery and classification to 80% in follow-up forecasting. Category estimates use available same-Task comparisons and therefore retain unequal coverage.

Cost alone did not determine performance (Figure 4B). On the eleven shared Tasks, the efficiency frontier comprised Llama 4 Maverick (40% win rate; \$0.00021 per call), GPT-5.6 (62%; \$0.00041) and Gemini 3.7 Flash (83%; \$0.0015). Gemini 3.7 Flash outperformed every more expensive model, including Opus 4.8 at \$0.010 per call. Full cost, reliability and all-Task estimates are shown in Supplementary Figure 3.


Fitted probes provided a reference for interpreting these capability profiles. On phenotype recovery the median full-packet R^2 of the best model was 0.04 and of the weakest -0.34 ; models exceeded the demographic floor on at most 5 of 25 Tasks (Opus 4.8) and exceeded the ridge probe over the same fields in 9 of 304 model–Task cells. In classification the best models matched the demographic classifier (median AUROC 0.75 versus a floor of 0.77) and exceeded the logistic comparator in 10 of 66 cells, most of them on migraine, where that comparator itself fell below the floor. In ordering no model’s pairwise accuracy exceeded the ordering induced by the ridge probe on five of six Tasks. Follow-up forecasting was the one category where most models beat the demographic floor (3 of 4 Tasks for twelve models), because the baseline value of the target was disclosed; against the informative comparator, simply carrying the baseline forward, models added R^2 of $+0.02$ to $+0.10$ on systolic blood pressure but -0.06 to $+0.06$ on the apnea–hypopnea index, and the ridge probe with the same fields added more. Absolute per-Task estimates and probe references are shown in Supplementary Figures 3 and 5.

The same controlled Tasks exposed failure modes that aggregate rankings conceal. Across the 11-Task map, the median Task-Card change in Spearman correlation ranged from -0.017 to $+0.026$ across four models, while the median change in R^2 ranged from 0.000 to $+0.019$. These aggregate changes coexisted with task-specific units and target-semantics failures: on retinal artery width every model answered on a micrometre-like scale against a target in AutoMorph pixels (bias $-18,500$ pixels, spread near zero), and on liver attenuation most models placed estimates on the wrong scale. The Task Card, which supplies HPP reference values, repaired the liver-attenuation scale; retinal artery width remained off-scale under both card versions. Parse failures were rare (below 0.2% for every retained model) and Pixtral Large lost 10.7% of calls to transport errors, which were excluded rather than imputed (Supplementary Figure 3).

This evaluation used one run per cell, 150–480 validation participants per Task, a fixed packet of summary features and a single prompt family. The contribution is a controlled cohort-data evaluation of model capability profiles, efficiency tradeoffs and clinically relevant failure modes. Fitted-probe comparisons calibrate how much predictive information the language models extract from the same evidence.

A EVALUATION CONTRACT

Same participants, evidence, target and metric across models

**B REPRESENTATIVE QUESTION**

Phenotype recovery · HbA1c · fixed validation split

QUESTION

Estimate this participant's HbA1c, measured at the same study visit, in percent.

EVIDENCE PACKET

Age · sex · BMI · CGM summary · Nightingale NMR metabolomics

RESPONSE SCHEMA


```
{
  "hba1c_percent": <number>,
  "reasoning": "<one or two sentences>"
}
```

SCORING


R^2 and MAE against measured HbA1c under the fixed PhenoBench Task contract

Supplementary Figure 2 | PhenoBench-LLM evaluation contract and representative question. **A**, Every model receives the same participant-level HPP evidence under a frozen question and response schema. Predictions are stored as Imported Prediction Artifacts and scored against the fixed target, validation split and metric owned by the PhenoBench Task. **B**, Representative HbA1c phenotype-recovery question and response schema. The evidence fields and wording are the task template; no participant row or model response is reproduced.


LLM leaderboard and task-level detail



Supplementary Figure 3 | PhenoBench-LLM leaderboard and Task-level detail. **A**, Category leaderboard and all-Task pairwise win rate; cells represent median full-packet performance and the fraction of Tasks beating the demographic floor. **B**, Mean cost per call against all-Task win rate; numbers index the leaderboard rank and intervals are Task-bootstrap 95% confidence intervals. **C**, Absolute full-packet performance for every model and point-estimation Task, with participant-bootstrap intervals, demographic floors and fitted-probe references. Off-scale R^2 values are retained in the source table and marked at the axis edge.



Supplementary Figure 4 | PhenoBench-LLM paired and mechanistic analyses. **A**, Paired MAE effects of evidence arms and the fitted probe for HbA1c and VAT mass. **B**, HbA1c shuffled-packet control. **C**, Per-Task full-packet difference from the fitted probe. **D**, Grouped-ranking pairwise accuracy with random, demographic-order and ridge-order references. **E**, Cross-Task map of full-packet R^2 lift over demographics, ordered by fitted-probe lift. **F**, sanitized Task Card R^2 shift over the full packet. Off-scale heatmap values are printed and hatched. All comparisons use the validation split and retain null and negative estimates.

A TASK-LEVEL EFFECTS AGAINST FITTED PROBES

Supplementary Figure 5 | Task-level PhenoBench-LLM effects against fitted probes. Each marker is one model's full-packet primary-metric difference from the ridge or logistic probe over the same fields; zero denotes the fitted probe. Grey ticks show the demographic-floor difference from the probe and grey squares show the Task Card arm where available. Values outside ± 0.3 are marked at the edge and retained exactly in the source table. Tasks are grouped by phenotype recovery, classification and longitudinal forecasting; grouped ranking is shown in Supplementary Figure 4.

E. Extended methods

E.1. Cohort and measurements

The Human Phenotype Project (HPP) is a prospective longitudinal cohort with broad clinical, molecular, imaging, and wearable phenotyping [19]. Measurements include medical history and lifestyle, anthropometrics, blood assays, continuous glucose monitoring (CGM), overnight sleep physiology, imaging, and multi-omic assays. PhenoBench analyses use task-specific eligible subsets rather than one common cohort: each Task defines its target, timepoint, required measurements, quality-control rules, exclusions, and evaluation grain.

Unless a Task specifies a documented alternative, participants are assigned by a stable participant-identifier hash to canonical 70/15/15 train, validation, and test splits (`participant_id_split_v1:0.7,0.15,0.15`). Repeated observations are grouped by participant so that one person does not cross splits. Imputation and fitted preprocessing use training data only; model and hyperparameter development use the validation split, and the held-out test split is fired once for a reviewed final result. Event- or artifact-based Tasks record any different grouping or split policy in their executable contract.

HPP participants provided informed consent, and identifying details were removed before computational analysis. The study was conducted according to the Declaration of Helsinki and approved by the Weizmann Institute of Science Institutional Review Board (approval 2392-4) [19]. PhenoBench reports aggregate evaluation results and does not release individual-level participant data.

E.2. Benchmark tracks and model comparisons

We defined a model-comparison cell by task, cohort, predictor, and evaluation split. Within a cell, the target, participants, feature set, and split were fixed while the fitting method varied. The regression capacity analysis used complete-case cells in which all six prespecified methods were available: ridge, gradient boosting, RealMLP, TabSwift, TabICL, and TabDPT. This yielded 160 test-set comparison cells spanning 52 tasks. All six methods were selected from the committed PhenoBench v0 result boards under a common engine revision; all 828 repeated shared configurations across the two engine revisions were bit-identical.

Ridge and histogram gradient boosting were fitted conventionally on the task training data. RealMLP [26] was likewise trained from scratch (pytabkit 1.7.3); it is included as a strong neural tabular baseline, not labeled as a pretrained foundation model. TabSwift [20], TabICL [6], and TabDPT [27] used frozen pretrained checkpoints under their pinned benchmark implementations. All methods received the same columns and participants within a cell; model-specific preprocessing and ensembling followed the persisted run configuration.

For each method, we calculated ΔR^2 as its full-model test R^2 minus the common demographics-only ridge baseline from the matched ridge run. Demographics comprised age, sex, and BMI, with age omitted when chronological age was the target. Using one baseline made within-cell ranks identical to ranks based on raw R^2 . For non-ridge methods, this common reference means that ΔR^2 combines differences in fitting demographics with differences in using the added predictors. Cells missing any of the six methods were excluded from the complete-case capacity analysis.

The time-series comparison used frozen, zero-shot Chronos-2 embeddings of CGM, electrocardiography (ECG), and overnight sleep recordings with a ridge head. Each embedding route was compared only with features engineered from the same signal. To complete the comparison grid, 52 engineered-feature partners were derived from the corresponding Chronos-2 configuration by changing only the predictor; task arguments, split, strategy, and penalty grid were retained. The 31 glucose pairs were matched on task and cohort. The 32 sleep pairs were matched on task only because the engineered and embedding routes shared no cohort; each route used its own supported participant set. ECG contributed no pair because no engineered ECG feature set exists in the corpus. This analysis therefore compared representation routes under a linear head; it did not test whether a tabular foundation model could use the embeddings differently.

E.3. Statistical analysis

For the six-method analysis, we ranked methods within each comparison cell, with rank 1 denoting the highest ΔR^2 , and summarized mean ranks with percentile 95% intervals from 5,000 cell-level bootstrap resamples

(fixed seed 20260828). We used the Friedman test as an omnibus test that at least one method differed. For the ordering-free contrast, we compared the within-cell mean ΔR^2 of TabSwift, TabICL, and TabDPT with that of ridge and RealMLP using Wilcoxon signed-rank and exact binomial sign tests. We tested the ordered capacity sequence ridge, RealMLP, TabSwift, TabICL, and TabDPT using Page’s ordered-alternative test [28]; gradient boosting was excluded from this sequence because it did not define a monotone capacity step. For all 15 paired method contrasts, we calculated both a Wilcoxon signed-rank test and an exact binomial sign test, corrected each family separately with the Holm procedure, and called a contrast robust only when both adjusted p values were below 0.05. The signed-rank test uses difference magnitudes and assumes symmetric paired differences, whereas the sign test uses only their directions. Panel B reports Tukey box plots descriptively, with whiskers extending to 1.5 times the interquartile range and outliers omitted.

We quantified task- and feature-set-associated variation using η^2 and 5,000 permutations. Task labels were permuted freely; feature-set labels were permuted within task because feature set was nearly nested in task. The comparison cell was the inferential unit for method contrasts, so the 160 cells should not be read as 160 independent clinical questions. For correlates of model advantage, we first aggregated to the 52 task-level units. For each same-signal Chronos-2 comparison, we applied a paired Wilcoxon signed-rank test and an exact binomial sign test at its available matching unit: task and cohort for CGM, and task only for sleep.

E.4. Clinically grounded evaluation tasks

We began by asking which clinical and scientific questions could be answered using the HPP and which measurements could be used to answer them. The first source was selected publications based on the HPP cohort: these studies provided questions that had already been answered, or that investigators had attempted to answer, using the same participants and measurements. A clinician-authored inventory of surrogate targets provided an additional starting point, and later benchmark work broadened the collection beyond questions represented in the initial papers. These additions complemented the publication-led ingestion process rather than defining a separate primary route.

We first piloted this review on selected HPP publications and then applied it to a curated corpus of 61 materialized HPP paper objects. An agent-assisted pass used paper metadata, structured summaries, prior replication records, and targeted full-text checks. Six paper objects lacked enough body text or summary material for rigorous interpretation and were marked as evidence gaps rather than treated as studies with no usable task. The screen produced 31 candidate asset families. These counts describe the ingestion audit, not the provenance of every task in the final 90-task collection. Detailed audit outcomes are reported in the Appendix.

The paper review used structured extraction to turn prose into candidate task definitions. For each relevant result, we recorded a short task name, the clinical or scientific question, target, cohort and timepoint, information source, model or analytic strategy, metric, reported result, and split protocol. This step was closer to identifying and linking the parts of a question than to summarizing the paper as a whole. We did not translate each paper, or each extracted result, into a new Task.

We next assembled the clinical context needed to interpret each candidate. This included the source publication, targeted literature searches supported by Paperclip, and relevant OpenEvidence query responses that were manually examined by a clinician. We used this material to compose Task Cards describing why each target matters, how it is measured in HPP, meaningful baselines and comparators, leakage and confounding risks, measurement noise, suitable metrics, relevant evidence, and the claims a result could and could not support. In the converged process, each human-readable card was reviewed before the executable task was finalized.

We then mapped the extracted question onto the PhenoBench components: Task, Predictor, Strategy, configuration, metric, artifact, and evaluation record. A distinct target, target construction, eligible population, or scoring policy could justify a new Task. A different information source, representation, model, or visit pairing normally became a new Predictor, Strategy, or configuration for an existing Task.

Candidate validity and implementation readiness were assessed separately. Validity asked whether the target and proposed comparison formed a coherent scientific or clinical question, including whether the target was measured with the required units and timing, whether the eligible cohort could support the claim, and whether leakage or circularity made the comparison uninterpretable. Readiness asked whether the necessary data

route, artifact, target shape, split policy, metric, and provenance already existed. A valid candidate was therefore retained as future capability or artifact work when it could not yet be executed safely; missing software support was not itself a reason to reject the question.

For accepted targets, we froze an executable contract before interpreting model performance: target construction and units, evaluation-unit grain, exclusions and quality control, timepoints, participant grouping and data splits, primary and secondary metrics, and the minimum meaningful baseline. Information sources and model-specific inputs were kept outside the Task contract so that the same question could be asked of multiple measurements and methods under matched conditions.

After implementation, we reconciled the Task Card against the executable Task, configuration, HPP dataset documentation, and original literature. Agent assistance and literature tools accelerated extraction and evidence retrieval, but did not decide whether a question was clinically meaningful or whether a comparison supported a claim. Manual clinical examination of the supporting material was distinct from formal domain-expert adjudication of every card; unresolved measurement-sensitive decisions remained explicit, and expert-review status required review by the relevant domain expert.

An implemented candidate was considered reviewable only after synthetic contract checks and a real-data run. We inspected cohort and split counts, target and predictor support, the persisted run manifest, comparison with the declared baseline, and any contamination or provenance warnings. Paper-derived rows were labeled as paper-faithful, paper-inspired analogues, weak, or non-comparable according to whether the cohort, target, features, preprocessing, split, and metric supported the comparison. A runnable configuration alone did not establish that a published result had been reproduced.

E.5. Model onboarding and model cards

Task curation defines the question; model onboarding defines the system used to answer it. A Model Card documents a model family: an encoder together with the inputs it consumes. A version is a retrain within that family; a model we never retrain carries no version. We wrote cards for contributed models whose output enters an evaluation as a versioned artifact. Predictors defined inside the benchmark, the generic evaluation Strategies, and analysis controls carry no card.

A contributed model may have been pretrained on participants it is later scored on. Each Predictor therefore declares its upstream training exposure from a fixed vocabulary: no upstream model, no HPP training, HPP training restricted to the canonical train split, HPP training on another split, unknown, or undeclared. Where the producer files the list of participants the model trained on, we derive the exposure from that list and intersect it with the cohort the run scored. The ranking gate reads that intersection first and falls back to the declaration only when either list is unknown; a declared HPP-other-split exposure is excluded, an unknown exposure remains explicit, and an undeclared exposure is refused for exportable configurations. Both values stay on the manifest, so a wrong declaration stays visible. Two lists are filed so far; the CGM encoder’s spans all three canonical splits (5,198 train, 1,181 validation, 1,178 test), so rows using it are scored partly on participants it trained on.

Contributed models are frozen when evaluated, and any fine-tuning happened upstream under its own model identity. The only components fitted on PhenoBench training data are the probe head and its regularization strength, cross-validated within the training folds. A checksum-bound provenance document names the model, the artifact bytes, the participants, and the information sources the artifact may claim. An evaluation refuses an artifact whose bytes disagree with it. A changed configuration receives a new atomic identifier. We keep the card with the repository that produces the model, and its identifier links a run manifest or published result to it. For future contributions, the card is also the review surface for model source and license, accepted inputs and preprocessing, and the inference environment; these remain narrative rather than code-enforced fields.

We develop on the validation split only. Our release protocol requires a signed review, a single held-out test evaluation, re-derivation of its numbers from the persisted manifests, and a leaderboard commit by a second owner. The card then records that conclusion and the claim boundary: an evaluation measures predictive association, not causal effect or clinical utility, and a representation that recovers what its recording device already measures shows instrument read-back, not phenotype transfer. A card also records what its representation provably cannot encode. For example, Chronos-2 CGM embeddings are invariant to glucose level and variability, so the scored embeddings append the level and scale they discard under their own model

identifier; a WatchPAT time series was sampled at 10 Hz, so it keeps pulse rate and loses pulse-wave shape, and a null result does not bound what a shape-preserving encoder could find in the same recording.

External model submissions use an OCI image pinned by an immutable digest, as specified in the public contribution guide (<https://github.com/galsapir/phenobench-benchmark/blob/main/CONTRIBUTING.md>). Maintainers run accepted images without network access against private task bundles mounted read-only; the image writes predictions to a separate output directory, and those predictions must pass schema and identifier-alignment validation before result curation. Schema-faithful synthetic bundles expose the same input and output contract without releasing participant data.

E.6. PhenoBench-LLM: external prediction evaluation

We evaluated whether frontier language models can use HPP multimodal evidence to predict hidden measured phenotypes beyond their public priors and beyond strong conventional baselines, under fixed PhenoBench contracts. The design was frozen on the canonical validation split before any full-panel inference was scored, and protected test gates were not inspected or consumed. Two existing PhenoBench Tasks were used unchanged: HbA1c (`blood_tests.bt_hba1c`, %) and total visceral adipose tissue mass from DXA (`dxa.total_scan_vat_mass`, g), both at the baseline visit with the participant as the evaluation unit and R^2 as the primary metric. Both targets are measured at the same visit as CGM and Nightingale NMR metabolomics in thousands of participants, so the same participant can be scored under every Allowed Information Set in a paired design. Splits follow the canonical split source and logic (`participant_id_split_v1`, a participant-identifier hash allocating 0.70/0.15/0.15).

For each Task, the Scored Cohort is a seeded (20260826) uniform sample of 150 validation participants with complete demographics, CGM, and NMR evidence, drawn without reference to the target. The HbA1c Task-eligible cohort comprises 3,970 participants, of whom 607 are in the validation split and 482 have complete evidence; the corresponding counts for VAT are 8,953, 1,454, and 920. Participant identifier lists are private; SHA-256 hashes of each list and the cohort counts are published in the cohort manifests.

Each arm is an Allowed Information Set and defines one Benchmark Track for both Tasks. The demographics arm discloses age, sex, and BMI. The CGM arm adds 19 connection-level iglu summaries from the participant's primary baseline connection; the NMR arm adds 33 Nightingale analytes averaged over baseline rows; the full arm combines all three sources. A closed-book arm discloses no HPP evidence and is scored in the analysis as a constant per-model prior rather than through an Eval Run, because a Track requires at least one HPP information source. For HbA1c, a shuffled-control arm gives each participant another participant's complete packet, including demographics (no self-matches; seed 20260826), so it tests whether any of the disclosed evidence is used rather than the contribution of CGM or NMR specifically. Packet validation enforces the leakage exclusions: no participant, visit, or stage identifiers; no target field; no DXA field of any kind; a forbidden-term scan per Task; and the CGM-derived glucose management indicator and estimated A1c (`iglu_gmi`, `iglu_ea1c`) withheld from every LLM arm and reserved as a heuristic comparator. Units are disclosed; the Task's valid target range is not. Fasting NMR glucose is a distinct same-visit measurement and is deliberately visible in the NMR arms, to the language models and to the ridge probe alike.

The prompt contract is frozen and hashed over the system prompt, user template, closed-book prompt, and output schema (HbA1c `bf37f465...`; VAT `87f2962b...`; full hashes in the figure package). The model must return strict JSON with a numeric prediction and a free-text reasoning field. Responses that do not parse are recorded as missing predictions and counted as failures; they are never imputed. Failure rates from parsing, refusal, and transport errors are reported per arm and model.

Four External Prediction Models were queried through OpenRouter [29] with pinned model identifiers and provider routing, fallbacks disabled, and unsupported parameters rejected: `anthropic/claude-sonnet-5` (provider `anthropic`), `openai/gpt-5.6-luna` (`openai`), `google/gemini-3.7-flash` (`google-ai-studio`), and `deepseek/deepseek-v4-pro` (`streamlake`). Reasoning effort was requested as low for every model; Claude reported zero reasoning tokens in every call, so its extended thinking was not engaged, whereas the other three models emitted reasoning tokens. The output budget was 1,200 tokens, raised to 4,000 for DeepSeek only after 129 of its first-pass calls exhausted the budget on reasoning and returned no content; every DeepSeek call was then re-issued and the first-pass records were retained as superseded. No other model reached the budget. Temperature was fixed at 0 for Gemini and DeepSeek; the Claude and GPT endpoints do not accept a temperature parameter and ran at provider-default decoding. The served model, provider, token counts, cost,

and generation identifier are recorded per call. Each model’s predictions enter PhenoBench as an Imported Prediction Artifact bound to the Scored Cohort and its Allowed Information Set.

Baselines are scored on the same 150 participants with the same visible fields. The demographic floor follows the canonical PhenoBench baseline contract. Cross-validated ridge probes (`ridge_cv`) fitted on the canonical training split of the Task-eligible participants who have the arm’s features provide the conventional comparator for the CGM, NMR, and combined arms. For HbA1c, the raw glucose management indicator [30] used directly as the prediction provides a heuristic comparator (on this cohort it scores below the demographic floor), and each model’s closed-book output provides its prior. Because the benchmark scores a pinned subset only after training on the remainder, baselines were run on the full Task-eligible validation cohort and their predictions restricted to the Scored Cohort in analysis.

The primary endpoint per Task is R^2 on the Scored Cohort; mean absolute error in native units is the display metric and is shown alongside R^2 . Prespecified paired comparisons within each model are the grounding lift from demographics to the full packet, the modality lift from demographics to CGM and to NMR, the difference between the LLM full arm and the ridge full arm, the difference between the LLM full arm and the GMI comparator (HbA1c), and the difference between the shuffled and full arms (HbA1c), which must favor the full arm for the evidence to count as used. Uncertainty for every difference is a paired bootstrap over participants with 2,000 resamples (seed 20260826) and 95% percentile intervals. No significance claims are made; every difference is reported with its interval, and mean signed error is reported alongside mean absolute error. Metrics are not averaged across Tasks and no post hoc composite model score is computed.

Three further External Prediction Models were queried through the Amazon Bedrock Converse API in the us-east-1 region, with pinned inference-profile identifiers: Claude Opus 4.8 (`us.anthropic.claude-opus-4-8`), Amazon Nova Pro (`us.amazon.nova-pro-v1:0`), and Llama 3.3 70B (`us.meta.llama3-3-70b-instruct-v1:0`). The output budget was 1,200 tokens for all three; temperature was fixed at 0 for Nova Pro and Llama 3.3 70B, and Claude Opus 4.8 ran at provider-default decoding. The output schema is appended to the system prompt and responses are parsed under the same strict JSON rule. Because the Converse API returns token counts but no cost field, the cost recorded per call is computed from token counts using the analysis configuration’s pinned list-price assumptions (USD per million input/output tokens: 5.00/25.00 for Claude Opus 4.8, 0.80/3.20 for Nova Pro, 0.72/0.72 for Llama 3.3 70B), not a billed amount. Each Bedrock call records the same raw provenance fields as the OpenRouter client. Together with the four OpenRouter models this forms a seven-model panel; the additions were frozen before any of their results were scored.

To test ordering without requiring a calibrated number, we defined two PhenoBench-LLM group-ranking Tasks, `hba1c_group_rank` and `vat_group_rank`, which delegate target construction, eligibility, and splits to the parent Task and only partition its validation participants into groups. For each parent Task, a named cohort of validation participants with complete demographics, CGM, and NMR evidence was capped at 480 by a seeded uniform sample and partitioned into 120 groups of four by a seeded random permutation (seed 20260826), so every participant sits in exactly one group. The Evaluation Unit is the within-group pair `group:a:b`, with participants ordered by identifier, and the target is 1 if $y_a > y_b$ and 0 otherwise; tied pairs are excluded at construction, leaving 672 of 720 possible pairs for HbA1c and all 720 for VAT. Participants in a group are labelled A to D by a seeded shuffle so that label order carries no target information. One prompt per group presents the four evidence packets under the arm’s Allowed Information Set (demographics or full packet) and asks for a ranking from highest to lowest; the response must be strict JSON whose rank list is a permutation of the labels (a leading “Participant” before a label and code fences are tolerated), and anything else is a failure that drops the group and is counted. The system prompt reused the point-estimation wording, which refers to one participant and a single estimate; the group instruction is in the user prompt. Because a failed group removes its pairs, accuracy is reported over scored pairs together with the number of failed groups and an abstain-scored sensitivity in which every pair of a failed group receives half credit. The rank list is encoded as one hard prediction per pair (1 if a is ranked above b), submitted as a `submitted_predictions` artifact and scored through prediction passthrough, so no new Output Channel was needed. The primary metric is pairwise accuracy, with an analytic chance level of 0.5 (a constant prediction of 0.5 receives half credit on every pair) and the mean per-group Kendall τ between true and predicted within-group orderings as an auxiliary metric. Conventional comparators are the ridge full-packet probe and the demographic floor, whose point predictions are ordered within the same groups and pair-encoded the same way. Because pairs within a group are not independent, uncertainty for each paired difference is a group-level paired bootstrap (groups resampled with

their pairs kept together; 2,000 resamples, seed 20260826) with 95% percentile intervals. Headline ordering win rates use scored pairs and can therefore reflect different retained pair subsets; abstain-scored accuracy is reported as a sensitivity analysis.

To ask where LLM grounding helps relative to conventional models, the same regression protocol was applied across 11 further existing PhenoBench Tasks. From 78 probing continuous-scalar Tasks we excluded any target that is a packet field or a transform of one (CGM summaries, NMR analytes and their laboratory twins, eGFR, TyG, FLI, body weight, chronological age) and chose, for domain spread, Tasks with at least 337 complete-evidence validation participants: resting heart rate from the 12-lead ECG (beats per minute), thigh-to-ankle pulse wave velocity (m/s), sitting systolic blood pressure (mmHg), liver ultrasound attenuation coefficient (dB/cm/MHz), serum uric acid (mg/dL), serum TSH (mIU/L), white blood cell count (10^3 cells/ μ L), apnea-hypopnea index from the overnight sleep study (events per hour), DXA femoral neck bone mineral density (g/cm²), gut microbiome Shannon diversity (nats), and retinal fundus artery average width (AutoMorph pixels). FIB-4 was also run but is excluded from the map: age is an ingredient of the FIB-4 formula, so PhenoBench refuses its demographic floor and the conventional lift is undefined; its calls are retained in the raw store and not analyzed. Each Task uses a seeded (20260826) sample of 150 complete-evidence validation participants with its own cohort manifest, three arms (demographics, full packet, and full packet with the Task Card) plus the closed-book prior, and four models: Gemini 3.7 Flash and GPT-5.6 via OpenRouter, Claude Opus 4.8 and Amazon Nova Pro via Bedrock. The card arm prepends to the full-packet prompt the PhenoBench Task Card rendered without its implementation facts, HPP data-source section, status lines, or any valid-range statement. The remaining card text is not purely clinical: cards quote HPP reference values (for example the cohort median and clinical thresholds for liver attenuation) and the benchmark’s own baseline rows with their errors, so the card conveys the measurement’s scale and typical spread as well as domain context. The card lift therefore measures the value of curated HPP-specific context including reference values, not clinical knowledge alone; to separate calibration from information, lifts are also reported on a scale-free metric, the Spearman correlation between predictions and targets. For each Task and model the LLM lift is $R^2(\text{full}) - R^2(\text{demographics})$ and the card lift is $R^2(\text{card}) - R^2(\text{full})$; the conventional lift is the ridge $\Delta R^2 = R^2(\text{ridge full packet}) - R^2(\text{demographic floor})$, from validation Eval Runs on the same fields and participants (ridge is scored on all 150; a model’s arm is scored on the participants it returned a parseable estimate for, at least 144 in every cell). Agreement between LLM lift and ridge ΔR^2 is summarized per model as Spearman ρ across Tasks with a Task-level bootstrap interval (2,000 resamples, seed 20260826). Because R^2 is unbounded below, an off-scale output for a few participants produces a large negative arm R^2 ; the tables report unclipped values, and the figure clips at ± 0.5 and marks clipped cells.

This evaluation used a single run, 150 participants per regression Task and 480 per ranking Task, a seven-model panel, and the validation split. It does not establish held-out performance, and if the shuffled control is not worse than the full arm for a model, evidence use is not demonstrated for that model. The aggregate leaderboard rows and Task Cards used as evidence are public; participant identifiers, evidence packets, raw requests and responses, and the Imported Prediction Artifacts with their provenance are held privately.

E.7. PhenoBench-LLM as a benchmark suite

The evaluations above were then organised into a benchmark suite, PhenoBench-LLM, in the manner of MedHELM [31]: a taxonomy of evaluation categories laid over existing PhenoBench Tasks, with one fixed evidence packet, one scoring path, and one pair of conventional comparators per category. The suite adds no new target constructions. Every entry is either an existing participant-level PhenoBench Task at the baseline visit, a PhenoBench-LLM group-ranking Task that delegates to such a parent, or an existing longitudinal Task configured with its follow-up visit as the target. Five categories are defined: phenotype recovery (estimate a hidden continuous measurement), classification (estimate the probability of a curated binary status), longitudinal forecasting (estimate a measurement at the follow-up visit from baseline evidence), ordering (rank participants within small groups), and card-conditioned context (any of the above with the PhenoBench Task Card prepended). Task-level Eval Units, cohorts, and metrics are unchanged; only the evidence packet and the response contract are supplied by the suite.

Membership was screened over the registered participant-level Tasks against the fixed demographics, CGM, and NMR packet. A Task was excluded if its target is a packet field or a transform of one (CGM summaries, NMR analytes and their laboratory twins), if a packet field is an ingredient of the target’s formula (eGFR, TyG, FLI, FIB-4, body weight, chronological age), if its label is a BMI threshold (BMI is disclosed, so the

demographic floor is definitional), if its label is a curated NMR-lipid phenotype (the packet contains the lipid analytes the label is derived from), or if its prevalence is too low for positive cases to be counted reliably in a Scored Cohort of 150. Meal-level, night-level, causal-effect, and retrieval Tasks are out of scope because the packet is participant-level. Within the eligible set, Tasks were chosen for domain spread. Each Task uses a seeded (20260826) uniform sample of complete-evidence validation participants as its Scored Cohort, with its own cohort manifest carrying counts and identifier-list hashes, and the same leakage validator, forbidden-term scan, and strict-JSON parsing rule as the point-estimation protocol.

Phenotype recovery comprises the two anchor Tasks and the eleven cross-Task map Tasks described above together with twelve further Tasks: sitting diastolic blood pressure (mmHg), QT interval from the 12-lead ECG (ms), mean carotid intima-media thickness (mm), liver stiffness by ultrasound elastography (kPa), DXA lumbar spine L1–L4 bone mineral density (g/cm²), maximum hand grip strength of the better hand (kg), blood hemoglobin (g/dL), serum ferritin (ng/mL), serum alanine aminotransferase (U/L), minimum nocturnal oxygen saturation from the overnight sleep study (%), sleep efficiency (%), and the minimum ankle-brachial index over both sides (ratio). The primary metric is R^2 with mean absolute error in native units alongside, as before. Classification comprises five curated HPP phenotypes, each a participant-level binary label built from measurements, diagnoses, questionnaires, or medication rather than from a threshold on any packet field: hypertension, metabolic-associated fatty liver disease, prediabetes or diabetes, hypothyroidism, and migraine. Irritable bowel syndrome was also screened and run but was dropped from the suite as the least informative classification Task; its records are retained in the raw store and excluded from tables and figures. The prediabetes Task is flagged as a glycaemic-proxy Task: NMR fasting glucose, a laboratory twin of one of the label’s criteria, is visible in the packet, so it tests a proxy rather than a clean curated phenotype. Because the prevalence of hypothyroidism and of migraine in the complete-evidence validation pool is low, their Scored Cohorts are seeded uniform samples of 300 rather than 150 participants, so that the expected number of positive cases supports a rank-based metric. Longitudinal forecasting comprises four Tasks whose parents are already in the suite: sitting systolic and diastolic blood pressure (mmHg), liver ultrasound attenuation coefficient (dB/cm/MHz), and apnea-hypopnea index (events per hour), each with the target measured at the follow-up visit about two years after baseline. Ordering comprises six PhenoBench-LLM group-ranking Tasks with the protocol described above: the two described earlier (HbA1c and VAT) and four whose parents were admitted by the same rule (a demographic floor R^2 between 0.05 and 0.7 and at least 480 complete-evidence validation participants): sitting systolic blood pressure, apnea-hypopnea index, mean carotid intima-media thickness, and femoral neck bone mineral density. Further parent Tasks that satisfy the rule are listed in the taxonomy as candidates. The card-conditioned category re-uses the Tasks of the other categories and adds no cohort of its own.

For classification Tasks the model is asked for the probability, between 0 and 1, that the participant carries the curated status as determined at the same study visit; the output schema bounds the number to [0, 1], and a response outside the bound or not parseable as strict JSON is a failure. Probabilities enter PhenoBench through the same participant-prediction passthrough as the continuous Tasks and are scored by the benchmark’s binary-classification path. The primary metric is the area under the receiver operating characteristic curve (AUROC), which does not depend on the calibration of the returned probabilities; the Brier score is the secondary metric and does. The floor is the canonical PhenoBench demographic classifier floor, a logistic regression on age, sex, and BMI fitted on the Task’s training split. The conventional comparator is a logistic regression fitted on the training split over exactly the fields visible in the arm (demographics with CGM, with NMR, or with both), returning probabilities, so that the comparator for a classification Task plays the role the ridge probe plays for a continuous Task. As for the continuous Tasks, baselines are run on the full Task-eligible validation cohort and restricted to the Scored Cohort in analysis.

Longitudinal Tasks are existing PhenoBench scalar Tasks configured with the follow-up visit as the target stage and the baseline visit as the covariate stage; eligibility requires a finite baseline value of the target, and the Scored Cohort is drawn from validation participants with complete baseline evidence and a follow-up measurement. The evidence packet is the baseline packet of the parent Task with one additional block: the baseline value of the target itself, in the same unit. This block is disclosed in every arm, to the language models and to the ridge comparator alike, and the leakage validator admits it for follow-up Tasks only; the prompt states that all evidence, including the baseline value of the same measurement, was measured at the baseline visit. The question is therefore whether the model can use the baseline packet to anticipate change over roughly two years, not whether it can reproduce a value it has already been given. Scoring is R^2 on the follow-up value, with the demographic floor, the ridge probe over the same fields (baseline value included),

and a baseline-carry-forward comparator that predicts the baseline value itself as comparators. Because the follow-up value is dominated by its autocorrelation with the baseline, R^2 on the follow-up value is high for any estimate close to the disclosed baseline, and the paired comparison with the carry-forward comparator is the informative one; R^2 on the change score was not prespecified and is not reported.

The External Prediction Model panel of the suite comprises fourteen models: the seven described above, two further Bedrock models, and five further OpenRouter models. Pixtral Large 2502 (us.mistral.pixtral-large-2502-v1:0, temperature 0) and Claude Haiku 4.5 (us.anthropic.claude-haiku-4-5-20251001-v1:0, provider-default decoding) were added through the Amazon Bedrock Converse API in us-east-1 with a 1,200-token output budget and cost computed from token counts and pinned list prices (USD per million input/output tokens: 2.00/6.00 and 1.00/5.00 respectively). Amazon Nova Premier and the Bedrock Llama 4 profile were also requested but the account was denied access to both inference profiles, so neither was called. The OpenRouter additions were chosen for spread across developers, model sizes, and release dates among models that support a JSON output schema, and each is pinned to a single provider with fallbacks disabled, as before: Gemini 3.1 Pro (google/gemini-3.1-pro-preview, google-ai-studio), GPT-5.4 nano (openai/gpt-5.4-nano, openai), Gemini 3.1 Flash-Lite (google/gemini-3.1-flash-lite, google-ai-studio), Llama 4 Maverick (meta-llama/llama-4-maverick, deepinfra), and Grok 4.3 (x-ai/grok-4.3, xai). Temperature was fixed at 0 wherever the endpoint accepts it; the GPT-5.4 nano endpoint does not and ran at provider-default decoding. Reasoning effort was requested as low, except minimal for GPT-5.4 nano and none for Llama 4 Maverick, which does not emit reasoning tokens. The output budget was 1,200 tokens, set to 4,000 from the outset for Grok 4.3 and the reasoning-emitting open-weight models, which emit reasoning tokens that count against the budget, so that the truncation seen for DeepSeek under the smaller budget could not recur. Because per-call cost scales with the number of Tasks, the two most expensive additions, Gemini 3.1 Pro and Grok 4.3, were run on a prespecified subset only: the thirteen point-estimation Tasks of the evaluations described above, three classification Tasks, and the six ranking Tasks. Gemini 3.1 Pro and Grok 4.3 each covered 22 of the 40 Tasks; in the final retained records, Claude Sonnet 5 and DeepSeek V4 Pro each covered 29, and the other ten models covered all 40. The 22-Task subset was fixed before either model's results were scored, and the number of Tasks each model was run on is reported alongside every summary of it. Each addition was frozen before any of its results were scored. Three further open-weight models, Qwen 3.8-27B, Mistral Large 2512, and GLM-5.2, were started and withdrawn before completing the suite because their per-call latency made them the limiting step; their partial records are retained but excluded from every table and figure.

Two prompt components were revised for the suite, and both revisions are versioned so that their raw records never collide with the earlier ones. The Task Card renderer (v2) keeps the card's clinical sections and, in addition to dropping the HPP data-source section, implementation facts, status lines, and any valid-range statement as before, drops every table, every section whose heading refers to the benchmark, its baselines, variants, final-test or leaderboard results, and every line that quotes a number with a unit or a summary statistic (medians, means, standard deviations, error metrics, thresholds, percentiles, or sample sizes). The v2 card therefore conveys the measurement's clinical meaning and the reasons it matters without the reference values that let the v1 card fix the target's scale, and the card lift under v2 is interpretable as the value of curated domain context rather than of disclosed reference values. The grouped-ranking system prompt (v2) instructs the model that it is comparing several participants and must return their ordering, replacing the re-used single-participant point-estimation system prompt of the first ranking run; the user prompt and output schema are unchanged. The card and ranking arms in the suite use the v2 components. The v1 card-arm results reported above are retained as sensitivity rows in the tables and are not re-scored; where the same Task appears under both versions, the two are shown side by side.

The suite is summarised in a leaderboard with two levels. The per-Task level has one row per Task and model: the model's full-packet score on the category's primary metric (or, for ordering, its pairwise accuracy), the demographic floor and the conventional probe on the same fields and participants (for ordering, the floor-ordering and ridge-ordering comparators), the paired differences of the model from each, and the model's demographics-only and card-conditioned scores where those arms were run. The category level summarises, for each category and model, the number of Tasks, the share of Tasks on which the model's full arm exceeds the floor and the share on which it exceeds the conventional probe, the mean and median of the paired differences, and the model's mean rank among the language models across the category's Tasks (rank 1 is best, ties averaged). Ranks are computed within a Task, so they compare models to one another and not across Tasks. No composite score is formed across categories, because the primary metrics (R^2 , AUROC, pairwise

accuracy) are not commensurable and the Tasks are not a probability sample of anything. The leaderboard is descriptive: it uses a single run per cell on the validation split with a fixed evidence packet, its per-Task differences carry the paired bootstrap intervals described earlier, and its category summaries do not support general model rankings. It claims where, on these Tasks and this evidence, a model’s full-packet estimate does or does not exceed the demographic floor and a conventional probe fitted on the same fields; it does not claim held-out performance, a ranking of models in general, or that the categories are exhaustive of the questions PhenoBench can ask. Three further leaderboard statistics compare the models with one another rather than with the comparators. The win rate, adapted from MedHELM [31], is computed over all pairs of models: for every Task on which both models of a pair have a full-packet score, the model with the higher primary metric wins the head-to-head and a tie counts half for each; a model’s win rate is the share of its head-to-heads won. Its 95% interval is a percentile interval from a Task-level bootstrap (Tasks resampled with replacement, 2,000 resamples, seed 20260826), so it reflects sensitivity to the Task set rather than to participants. Because a head-to-head requires both models to have been run on the Task, the win rate is reported at two levels: the headline win rate for cross-model comparison is computed on the common Task set, the Tasks that every retained model ran, and a secondary win rate is computed over all available head-to-heads, with each model’s Task count alongside; on the secondary rate a model run on a subset of Tasks is compared only on that subset and is comparable with the full-suite models descriptively, not inferentially. Each leaderboard cell (one Task, one model, full-packet arm) carries a participant-level bootstrap interval of its primary metric (R^2 or AUROC; 1,000 resamples, seed 20260826, 95% percentile), computed over the participants for whom the model returned a parseable estimate. At Scored Cohorts of 150 or 300 participants the AUROC intervals are wide (0.11–0.35), so differences between models, and between a model and the logistic comparator, on the classification Tasks are descriptive only; where a fitted comparator scores below the demographic floor on the Scored Cohort, as the logistic comparator does for migraine, the floor is the operative comparator for that Task. One Task, retinal fundus artery average width, exposes a unit-scale failure shared by every model: the target is in AutoMorph pixels and every model answers on a μm -like scale, so every estimate is off-scale; the Task is retained in the tables as a contract-following failure. Cost per call is the mean over the model’s non-errored calls of the recorded cost, which is the OpenRouter-reported amount for OpenRouter models and the token counts priced at the pinned list prices for Bedrock models, together with mean prompt and completion token counts. Two failure rates are reported per model across its Tasks: the transport-error rate, the share of calls that returned no response, and the parse-failure rate, the share of returned responses that were not strict JSON. A prespecified failure-mode table, computed from the full-packet arm of each continuous Task, reports per Task and model the abstention rate (the share of requested participants without a parseable estimate), the off-scale rate (the share of estimates further than three cohort standard deviations from the cohort mean of the target), the bias (mean signed error in units of the cohort standard deviation), and the spread ratio (the standard deviation of the estimates divided by that of the target), so that a poor R^2 can be attributed to a few off-scale outputs, a systematic offset, or compressed predictions.

The main figure separates capability profile from efficiency under the fixed cohort-data contract. Panel A reports each model’s within-category pairwise win rate using only same-Task head-to-heads, with unequal category coverage retained explicitly. Panel B reports common-Task pairwise win rate against mean cost per call and identifies the Pareto frontier. The evaluation contract and representative question, conventional-probe references, absolute per-Task estimates, paired evidence analyses, Task Card effects, failure modes, and reliability details are reported in the text and Supplementary Figures. The taxonomy, cohort-level manifests, evaluation settings, leaderboard tables, and metric code are public.

F. Extended limitations

The question set is broad but uneven and reflects the questions formulated and implemented so far. Some empirical comparisons jointly change the measurement and its representation, so they estimate the value of the complete route. The screening analyses span many questions without multiplicity adjustment, and their predictive associations do not establish causality or clinical utility. HPP-specific recruitment, measurement protocols and missingness may also limit transfer to other cohorts.

The model comparisons cover only tasks compatible with each method’s input and output requirements. The 160 complete-case cells are nested within 52 tasks and are not independent clinical questions; this post hoc cross-task synthesis was not preregistered. For non-ridge methods, ΔR^2 relative to the common ridge-fitted demographic baseline combines differences in fitting demographics with differences in using the added

predictors, and uncertainty summarizes variation across cells rather than paired prediction uncertainty within each cell. In the same-signal analysis, sleep pairs were not cohort-matched, ECG lacked an engineered comparator, and only a ridge head was tested on embeddings with 770–3,076 dimensions; no tabular foundation model was evaluated on them. The machine-querying experiment is a proof of concept; repeated epochs reused the same questions, and results depend on the tested prompts, tools, harness, and provider implementations. Neither analysis supports a general model ranking or clinical utility.

The cohort-grounded language-model evaluation used one run per cell on validation cohorts of 150–480 participants, a fixed packet of summary features and one prompt family. Category estimates retain unequal Task coverage, common-Task win rates summarize sensitivity to the tested Task set, and cost estimates combine provider-reported amounts with token counts priced from pinned list prices. The results do not establish held-out performance, general model superiority or clinical utility.

A participant-level holdout prevents direct overlap between training and test participants within an analysis, but it does not preserve independence under repeated use of the same cohort. Later choices of outcomes, features and models can be informed by earlier results even when every analysis uses a clean split [8,10]. This concern is familiar in large biobanks, where discovery and replication may share data-collection and processing dependencies [9], and reporting may not establish whether evidence was independently replicated [11]. Expansion therefore increases the need for prospective task definitions, versioned results, protected test tasks and independent-cohort validation. PhenoBench provides standardized internal evidence; external validation remains necessary for claims intended to generalize beyond HPP.

G. LLM usage disclosure

Large language models were evaluated as part of this study and were also used for agent-assisted task curation, manuscript editing, and verification. All outputs, analyses, citations, and text were reviewed by the authors.